Clinical Trials Sponsored by BerGenBio ASA

Total 3938 results

BerGenBio ASA

Completed

A Study of Bemcentinib for the Treatment of COVID-19 in Hospitalised Patients

COVID-19

India, South Africa
BerGenBio ASA

Recruiting

A Study to Investigate the Safety, Tolerability, and Preliminary Anti-tumor Activity of Bemcentinib in Combination With Pembrolizumab Plus Pemetrexed and Carboplatin in Adult Participants With Untreated Non-squamous Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

United States
BerGenBio ASA

Terminated

A Study of Tilvestamab (BGB149) in Relapsed, Platinum-resistant, High-grade Serous Ovarian Cancer (HGSOC) Participants

Ovarian Neoplasms

Korea, Republic of, Singapore, United Kingdom, Norway
BerGenBio ASA

Completed

A Study of BGB324(Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer

United States
BerGenBio ASA

Completed

A First-time-in-human Study of BGB149

Healthy Volunteers

United Kingdom
BerGenBio ASA

Active, not recruiting

A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDS

Acute Myeloid Leukemia | Myelodysplastic Syndromes

United States, Germany, Italy, Norway
Haukeland University Hospital
BerGenBio ASA

Active, not recruiting

BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic Melanoma

Melanoma

Norway
BerGenBio ASA
Merck Sharp & Dohme LLC

Completed

Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC

Lung Cancer Metastatic | Adenocarcinoma of Lung | NSCLC Stage IV

United States, Spain, United Kingdom, Norway
BerGenBio ASA
Merck Sharp & Dohme LLC

Terminated

Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC

Triple Negative Breast Cancer | Inflammatory Breast Cancer Stage IV

Spain, United States, United Kingdom, Norway
GWT-TUD GmbH
Amsterdam UMC, location VUmc; BerGenBio ASA; Groupe Francophone des Myelodysplasies

Completed

Evaluating the Efficacy and Safety of Bemcentinib in Patients With Myelodysplastic Syndromes

Acute Myeloid Leukemia | High-risk Myelodysplastic Syndrome | Low-risk Myelodysplastic Syndrome

Germany, Netherlands, France
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI); BerGenBio ASA

Terminated

AXL Inhibitor BGB324 in Treating Participants With Recurrent Glioblastoma Undergoing Surgery

Brain and Central Nervous System Tumors

United States
University of Texas Southwestern Medical Center
BerGenBio ASA; Translational Genomics Research Institute; Triligent International

Terminated

Clinical Trial of Chemotherapy and Bemcentinib for Metastatic Pancreatic Cancer

Cancer of Pancreas

United States
University of Texas Southwestern Medical Center
Texas Tech University Health Sciences Center; BerGenBio ASA

Completed

Trial of Dose Escalated BGB324 in Previously Treated Non-small Cell Lung Cancer.

Non-Small Cell Lung Carcinoma

United States
Nykode Therapeutics ASA
Vaccibody AS

Completed

A Phase 1/2 Study to Determine Safety and Immunogenicity of Two COVID 19 Vaccines VB10.2129 (RBD Candidate) and VB10.2210 (T Cell Candidate) Previously Vaccinated in Healthy Adult Volunteers

Infections | COVID-19 | Infection Viral

Norway
Nykode Therapeutics ASA
Theradex; Vaccibody AS

Completed

An Exploratory Safety and Immunogenicity Study of HPV16+ Immunotherapy VB10.16 in Women With HSIL; CIN 2/3)

High Grade Cervical Intraepithelial Neoplasia

Germany
Nykode Therapeutics ASA
Genentech, Inc.; Vaccibody AS

Active, not recruiting

Study of VB10.NEO in Combination With Atezolizumab in Solid Tumors

Solid Tumors, Adult

Spain, United States, Germany
Nykode Therapeutics ASA
Nektar Therapeutics; Vaccibody AS

Completed

A Study to Evaluate Safety and Efficacy of Multiple Dosing With VB10.NEO and Bempegaldesleukin (NKTR-214) Immunotherapy in Patients With Locally Advanced or Metastatic Cancer (DIRECT-01)

Locally Advanced or Metastatic Solid Tumours

Germany
Medistim ASA

Not yet recruiting

Collect Flow and Ultrasound Images of Coronary Bypass Grafts (CASES)

Cardiac Bypass Surgery (CABG)
Ultimovacs ASA

Completed

UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma

Malignant Melanoma

United States, Belgium, United Kingdom, Norway
Ultimovacs ASA

Active, not recruiting

TENDU Vaccine in Patients With Relapse After Primary Radical Prostatectomy

Prostate Cancer

Norway
Targovax ASA

Terminated

Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Advanced Primary and Recurrent Oncogenic RAS Exon 2 Mutant Colorectal Cancer

Rectal Cancer

New Zealand, Australia
Ultimovacs ASA

Active, not recruiting

A Phase I/IIa Study of UV1 Vaccine in Patients With Prostate Cancer (UV1/hTERT2012P)

Prostate Cancer

Norway
Medistim ASA

Not yet recruiting

Peripheral Bypass Trial for Completion Control (PATENT)

Chronic Limb-Threatening Ischemia
Ultimovacs ASA

Active, not recruiting

UV1 Vaccine With Pembrolizumab for Patients With Unresectable or Metastatic Melanoma

Malignant Melanoma

United States
Targovax ASA

Completed

Antigen-specific Cancer Immunotherapy (TG01) and Gemcitabine as Adjuvant Therapy in Resected Pancreatic Cancer

Pancreatic Cancer, Resected

Norway, Spain, United Kingdom
Medistim ASA

Completed

Registry for Quality Assessment With Ultrasound Imaging and TTFM in Cardiac Bypass Surgery (REQUEST)

Coronary Artery Bypass

United States, United Kingdom, Netherlands, Canada, Germany, Italy
Nykode Therapeutics ASA
Roche Pharma AG; Vaccibody AS

Completed

Investigating the Combination of VB10.16 and Atezolizumab in Patients With HPV 16-positive Cervical Cancer

Cervical Cancer | Cervix Cancer

Belgium, Germany, Bulgaria, Czechia, Norway, Poland
GlycaNova AS
OPIS USA

Recruiting

The Effect of LentinexHP® on Quality of Life in Stage IV Colorectal Cancer

Change in Mood | Change in Personality

Bulgaria
Biotec Pharmacon ASA

Completed

Efficacy and Safety Study of Soluble Beta-1,3/1,6-glucan (SBG) Versus Placebo in Chronic Diabetic Foot Ulcers

Diabetes | Diabetic Ulcer

Spain
Biotec Pharmacon ASA

Completed

Soluble Beta-glucan (SBG) as Treatment for Diabetic Foot Ulcers

Chronic Diabetic Foot Ulcers

United Kingdom
Biotec Pharmacon ASA

Completed

The Protective Effect of Soluble Beta-1,3/1,6-Glucan Compared to Placebo in Oral Mucositis in Head and Neck Cancer Patients

Oral Mucositis

Germany, United Kingdom
Biotec Pharmacon ASA

Completed

Efficacy of Soluble Beta-1,3/1,6-Glucan Compared to Placebo on Chronic Leg Ulcers in Diabetes Patients

Foot Ulcer

Russian Federation
Biotec Pharmacon ASA

Completed

Evaluation of Woulgan in Diabetic Foot Ulcer

Diabetic Foot Ulcers

United Kingdom, Sweden
Biotec Pharmacon ASA

Completed

Efficacy and Safety Study of SBG vs Placebo in Head and Neck Cancer Patients Undergoing Radiation Therapy

Head and Neck Cancer | Oral Mucositis

France
Biotec Pharmacon ASA

Completed

Effect of SBG in Patients With Breast Cancer

Breast Cancer

Norway
Biotec Pharmacon ASA

Completed

Safety of Soluble Beta-Glucan (SBG) in Treatment of Patients With Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma

Norway
Biotec Pharmacon ASA

Terminated

Efficacy and Safety Study of Soluble Beta-1,3/1,6-Glucan in Thermal Burns

Burns

Norway
Asan Medical Center
Korea Otsuka International Asia Arab

Completed

Trial of Cilostazol in Symptomatic Intracranial Arterial Stenosis II (TOSS-2)

Atherosclerosis | Cerebral Infarction

Philippines, Korea, Republic of, Thailand, Hong Kong
Charite University, Berlin, Germany
NSA, Collierville, TN, USA

Completed

Encapsulated Juice Powder Concentrate for Preventing Common Cold Symptoms

Common Cold

Germany
Regen Lab SA
RegenLab USA LLC

Completed

Evaluate the Clinical Effectiveness of RegenKit Platelet-rich Plasma (PRP) in Androgenetic Alopecia Treatment

Androgenetic Alopecia

United States
Targovax Oy

Completed

ONCOS-102 (Previously CGTG-102) for Therapy of Advanced Cancers

Malignant Solid Tumour

Finland
Targovax Oy

Completed

A Pilot Study of Sequential ONCOS-102, an Engineered Oncolytic Adenovirus Expressing GMCSF, and Pembrolizumab in Patients With Advanced or Unresectable Melanoma Progressing After Programmed Cell Death Protein 1 (PD1) Blockade

Advanced or Unresectable Melanoma Progressing After PD1 Blockade

United States, Norway
Ultimovacs ASA
Oslo University Hospital

Active, not recruiting

Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant Melanoma

Malignant Melanoma

Norway
Serodus ASA
The Research Council of Norway; Smerud Medical Research International AS

Completed

SER100 in Isolated Systolic Hypertension

Isolated Systolic Hypertension

United Kingdom, Finland, Hungary, Norway
Oslo University Hospital
Targovax ASA

Recruiting

The TG01 Study With TG01/QS-21 Vaccine in Patients With High-risk Smouldering Multiple Myeloma and Multiple Myeloma

Multiple Myeloma | Smoldering Multiple Myeloma

Norway
Ultimovacs ASA
Oslo University Hospital

Active, not recruiting

A Phase I/IIa Study of UV1 Vaccination in Patients With Non Small Cell Lung Cancer. (UV1-hTERT2012L)

Non-small Cell Lung Cancer

Norway
Targovax Oy
Theradex

Unknown

A Randomised Phase II Open-label Study With a Phase Ib Safety lead-in Cohort of ONCOS-102, an Immune-priming GM-CSF Coding Oncolytic Adenovirus, and Pemetrexed/Cisplatin in Patients With Unresectable Malignant Pleural Mesothelioma

To Determine Safety, Tolerability and Efficacy of ONCOS-102 in Combination With Chemotherapy

Spain, France
University of Bergen
Bergen Medical Research Foundation; Skretting ASA; Leroy Seafood Group ASA

Completed

A Study on the Possible Health Effects of Lean Fish and Fatty Fish Intake in Overweight or Obese Adults (FISK2)

Obesity | Overweight

Norway
University of Bergen
Bergen Medical Research Foundation; Skretting ASA; Leroy Seafood Group ASA

Completed

A Study on the Possible Health Effects of Lean Fish, Fatty Fish and Lean Meat Intake in Non-obese Adults (FISK1)

Obesity | Metabolic Disorders

Norway
University of Leicester
Eli Lilly and Company; GlaxoSmithKline; Merck Sharp & Dohme LLC; Roche Pharma AG; British Lung Foundation and other collaborators

Active, not recruiting

Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma (MiST)

Mesothelioma, Malignant

United Kingdom

Clinical Trials Sponsored by BerGenBio ASA

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Netherlands

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations